Treatment of 213 Patients with Symptomatic Tarlov Cysts by CT-Guided Percutaneous Injection of Fibrin Sealant

K. Murphy, A.L. Oaklander, G. Elias, S. Kathuria, and D.M. Long

ABSTRACT

BACKGROUND AND PURPOSE: There has been a steady progression of case reports and a small surgical series that report successful surgical treatment of Tarlov cysts with concomitant relief of patients' symptoms and improvement in their neurological dysfunction, yet patients are still told that these lesions are asymptomatic by physicians. The purpose of this study was to analyze the efficacy and safety of intervention in 213 consecutive patients with symptomatic Tarlov cysts treated by CT-guided 2-needle cyst aspiration and fibrin sealing.

MATERIALS AND METHODS: This study was designed to assess outcomes in patients who underwent CT-guided aspiration and injection of ≥ 1 sacral Tarlov cyst at Johns Hopkins Hospital between 2003 and 2013. In all, 289 cysts were treated in 213 consecutive patients. All these patients were followed for at least 6 months, 90% were followed for 1 year, and 83% were followed for 3–6 years. The aspiration-injection procedure used 2 needles and was performed with the patients under local anesthesia and intravenous anesthesia. In the fibrin-injection stage of the procedure, a commercially available fibrin sealant was injected into the cyst through the deep needle (Tisseel VH).

RESULTS: One year postprocedure, excellent results were obtained in 104 patients (54.2% of patients followed), and good or satisfactory results were obtained in 53 patients (27.6%). Thus, 157 patients (81.8%) in all were initially satisfied with the outcome of treatment. At 3–6 years postprocedure, 74.0% of patients followed were satisfied with treatment. There were no clinically significant complications.

CONCLUSIONS: The aspiration-injection technique described herein constitutes a safe and efficacious treatment option that holds promise for relieving cyst-related symptoms in many patients with very little risk.

ABBREVIATION: TC = Tarlov cyst

Perineurial Tarlov cysts (TC) are extrathecal CSF-filled cavities in the perineurial recesses around dorsal spinal nerve roots. Composed of vascularized connective tissue lined with flattened arachnoid tissue, TCs characteristically contain nerve root fibers and ganglion cells in their walls or cavities and tend to be sacral.^{1,2} They are also notable for their restricted connection to the subarachnoid space and thus exhibit delayed filling during spinal myelography.¹ The initial characterization

of these structures was cadaveric anatomic variants of unknown clinical significance^{3,4}; the neurosurgeon I.M. Tarlov recognized TCs in patients and established that some cause neurologic symptoms that can be cured neurosurgically.^{5–10} His 1953 monograph detailed their pathology, including compression and distortion of local nerves and hemorrhage.¹⁰ Ensuing work has established that TCs can cause axial sacrococcygeal pain; intrathecal hypotension; perineal pain; sensory loss; and bladder, bowel, and sexual dysfunction.^{11–13} Radicular symptoms have also been recognized,¹⁴ as have electrophysiologic correlates¹² and links to collagen dysfunction (eg, Ehlers-Danlos and Marfan syndromes).^{15,16}

Diagnosis preferentially begins with dedicated sacral MR imaging, which is more sensitive than CT or standard lumbosacral MR imaging.¹⁷ TCs are visualized (but not always reported) on 1%–2% of sacral MRIs, with approximately 25% of these believed to cause symptoms.¹⁸ It is often necessary to evaluate subarachnoid connectivity with myelography to distinguish TCs from intradural ectasias, subarachnoid cysts, and meningeal diverticula—cystic abnormalities that are frequently confused with TCs and for

Received February 22, 2015; accepted after revision June 13.

From the Department of Radiology (K.M., G.E.), University of Toronto, Toronto, Ontario, Canada; Departments of Neurology (A.L.O.) and Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Russell H Morgan Department of Radiology and Radiological Science (S.K.), Johns Hopkins Hospital, Baltimore Maryland; and Neuroscience Consults (D.M.L.), Lutherville, Maryland.

This work was supported in part by research grants from the US Public Health Service (NIH K24NS9892).

Please address correspondence to Kieran Murphy, MB, FRCPC, FSIR, Department of Radiology, Room 3 mc 424, Toronto Western Hospital, 399 Bathurst St, Toronto, ON, Canada M5T 2S8; e-mail: Kieran.murphy@uhn.ca

Indicates open access to non-subscribers at www.ajnr.org

<http://dx.doi.org/10.3174/ajnr.A4517>

which intracystic injection is contraindicated to avoid intrathecal spread and arachnoiditis.

Despite misimpressions in many clinical circles that TCs are always asymptomatic, there has been steady progress in developing the interventional treatments required for definitive management of symptoms. Conservative approaches including analgesic/anti-inflammatory medication and physical therapy have achieved varying degrees of success in reducing cyst-associated symptoms.¹⁹ Surgical methods, meanwhile, include lumbar-peritoneal and cystosubarachnoidal drainage and shunting^{20,21}; bipolar cautery to shrink cysts¹⁷; decompressive laminectomy²²⁻²⁴; and laminectomy with either total cyst resection,^{1,10,25,26} partial cyst wall resection,²⁷ or duroplasty/plication of cyst walls.²⁸ Despite standard limitations such as malfunction and infection after shunting, persistence of pain after laminectomy, and radicular deficits after ablative procedures, a prior review found that 88.6% of patients in the studies evaluated were satisfactorily relieved by surgery according to the outcome criteria of each report.¹⁴ Microsurgical techniques, such as laminectomies with electrophysiology-guided cyst wall fenestration/imbrication and myofascial flap repair and closure, are also used, and while these are potentially less effective, they appear to cause fewer adverse events and preserve neural tissue better.²⁹⁻³²

Minimally invasive percutaneous techniques have also emerged. In 1994, Paulsen et al¹³ reported immediate symptom relief lasting up to 3 months after single-needle aspiration of symptomatic TCs in 5 patients. Lee et al³³ then described using a patient's temporary response to cyst aspiration as a diagnostic maneuver to select candidates for surgery. In 1997, Patel et al³⁴ first described injecting autologous fibrin glue into aspirated cysts. Four of 4 patients exhibited marked improvement without recurrence during 23 months, with 1 achieving lasting relief. They postulated that fibrin deposition on cyst walls would impede CSF ingress, trigger fibrosis, and, ideally, promote cyst contracture. Zhang et al³⁵ subsequently reported that 100% of 31 patients treated with intracystic fibrin glue injection achieved satisfactory relief without recurrence during 28 months of follow-up. This methodology was further refined by the development by Murphy et al³⁶ of the 2-needle technique evaluated in this report. Maintaining an equilibrium of intracystic pressure during aspiration-injection, this procedure reduced pressure-related procedural radicular pain sometimes noted with the single-needle technique and perhaps improved fibrin sealant filling.

MATERIALS AND METHODS

Study Design

This study, initiated in 2003 after receiving institutional approval, assessed outcomes in all patients who underwent CT-guided 2-needle aspiration-injection of ≥ 1 symptomatic sacral TC at Johns Hopkins Hospital between 2003 and 2012. Assessments were repeated at 3 months postprocedure, 1 year postprocedure, and yearly thereafter.

Patient Selection

The study cohort was drawn from patients referred with apparently symptomatic sacral TCs. Although 6 patients were treated for cervical, thoracic, or lumbar TCs, these are not discussed here because they were too few to satisfactorily analyze. Referred pa-

FIG 1. Patient recruitment flowchart for aspiration-injection therapy.

tients were vetted for inclusion as illustrated in Fig 1. First, a diagnosis of TC was confirmed by scanning all patients with lumbar and sacral MR imaging to identify, characterize, and localize any cystic structures present. All studies were read independently by both an interventional neuroradiologist and a participating neurosurgeon. TCs were identified according to the classification criteria of Goyal et al² and Wilkins.³⁷ Patients in whom MR imaging inadequately defined subarachnoid connectivity underwent myelography to assess the rapidity of contrast spread into the cyst, and only those without significant connectivity (ie, those with slowly filling cysts) were considered for inclusion.

Depending on the seriousness of their condition and their willingness to enter the study, patients with imaging-confirmed sacral TCs were either referred to invasive surgery or considered for aspiration-injection treatment. Those who remained in consideration underwent further examination and testing to determine whether their symptoms could be attributed to visualized cysts (ie, whether their TCs were symptomatic). Confirmation of symptomatic cysts required that axial pain be in the immediate anatomic vicinity of the cyst, that radicular symptoms and signs occur only in the appropriate distribution of cyst-bearing segments, and that other potential pain generators be excluded by imaging or other diagnostic testing. Additionally, 104 patients in whom the symptoms of cysts were particularly uncertain underwent diagnostic sacral blockade of cyst-bearing roots; this was performed in the standard fashion through the most convenient posterior sensory foramen and used fluoroscopic or CT guidance to place a needle on the cyst-bearing root, superior to the cyst, and near the next root above. Pain relief commensurate with the agent used and lack of pain relief with control blocks were required for attribution of symptoms to the blocked cyst.

Exclusion Criteria. All patients with cystic abnormalities other than perineurial cysts and patients with cysts possessing considerable (wide-neck) direct communication with the subarachnoid space were rejected. Patients who lacked the ability to communicate in English; had the probability of inadequate follow-up (eg, those who lived outside North America); had any *Diagnostic and Statistical Manual of Mental Disorders* diagnosis; had unexplained

FIG 2. A, CT myelogram and myelogram showing minimal filling of a large right S2 Tarlov cyst with a narrow neck. There is significant remodelling of S2 and S3. B, With 18-ga spinal needles in place, one deeper than the other, partial aspiration has developed an air-fluid level. C, Injection of fibrin fills the cyst 80%. The volume of fibrin injected is close to the volume of CSF aspirated.

symptoms that were not clearly related to cyst-bearing roots or (as assessed by a neurosurgery nurse practitioner) the presence of ≥ 2 Waddell signs (to exclude patients whose pain may have considerable nonorganic components); and patients with any other probable identified pain generator besides TCs were also all rejected for treatment.

Physical Examination

All patients were seen by an experienced nurse practitioner who obtained a typical neurosurgical history with review of systems and medical history. All patients were also seen by a neurosurgeon and underwent history, physical evaluation of the spine, and neurologic evaluation, focusing on the symptomatic area of the spine. In addition, all patients underwent a detailed history and physical evaluation of the territories supplied by cyst-bearing nerve roots. All patients with pelvic, abdominal, or genital symptoms were also seen by a gynecologist and/or urologist. Urodynamics were obtained if recommended by the urologist.

Pain and function were evaluated by the Lumbar Spine Outcomes Questionnaire scale, a validated outcome measure in spinal disease that permits quantification of pain and neurologic loss (including bowel, bladder, or sexual dysfunction) and can be administered satisfactorily by telephone.³⁸ In addition to the severity measures, pain was also described in terms of its spatial and temporal characteristics, with aggravating and alleviating factors taken into account.

Treatment

All patients had a detailed discussion of treatment options including no treatment, pharmacologic pain management, invasive surgery, and aspiration-injection. That aspiration-injection was a new and novel technique was emphasized. All patients were given written material explaining these points in accordance with institutional review board guidelines. Patients who elected the aspiration-injection procedure were seen by the interventional neuroradiologist and were engaged in a second discussion of the procedure and its risks and benefits.

Method of Aspiration-Injection

All patients included in our cohort were treated by using the aspiration-injection technique previously described by Murphy et al.³⁶ Briefly, aspiration was preceded by performance of diagnostic CT (Aquilion 16-detector row multidetector CT unit; Toshiba Medical Systems, Tokyo, Japan) to select the level providing access to the cyst through the thinnest overlying bone. Sedation was induced intravenously. The back was prepared in the usual sterile fashion, with local anesthesia infiltrated into the skin, fat, muscles, and periosteum overlying the sacrum. Two 18-ga needles were advanced into the cyst with CT fluoroscopy (13 frames per second, 3 adjacent 2-, 4-, and 2-mm sections) (Fig 2). The tip of the first needle was typically placed deep in the cyst, while the second was placed more superficially. The stylets were removed from both needles, and fluid was aspirated via the deeper needle. The more superficial needle served as a venting tube during the aspiration process, allowing air to enter the cyst. Following aspiration, an air-fluid level developed; this was monitored intermittently with CT fluoroscopy for evidence of rapid cyst refilling, which would indicate a connection to the thecal sac. (We avoided using iodinated contrast agents to monitor cyst fluid levels because these fill up the cyst, complicate fibrin injection, and impair fibrin binding while providing no appreciable additional information compared with air-fluid levels). A commercially available fibrin sealant composed of human/bovine fibrin, fibrinolysis inhibitor, thrombin, and calcium chloride was next injected into the cyst through the deep needle (Tisseel VH; Baxter Healthcare, Deerfield, Illinois).

Following our observation that completely filling cysts with sealant often temporarily exacerbated postprocedural radicular pain (likely due to swelling sealant compressing the affected nerve root or nearby nociceptors), we adjusted the technique so that sealant injection was halted when CT fluoroscopy indicated that the cavity was approximately 75% full rather than 100% full. This step was found to address the postoperative pain issue without compromising efficacy. Both needles were then withdrawn, and the puncture sites were covered with an antibiotic ointment and a sterile dressing. Patients were observed for 2 hours after the completion of the procedure before being discharged. They were asked to stay locally for 1 night and were permitted to return to their normal physical activity immediately but were advised not to undertake strenuous physical exercise for 2–3 weeks. If multiple cysts were present, typically only 2 were treated per session, so some patients returned for repeat sessions.

Outcome Assessments

Outcomes were evaluated in the clinic or by telephone at 1 day and at 6 and 12 weeks postprocedure by an experienced nurse practitioner or a neurosurgeon. Lumbar sacral MR imaging was repeated at 12 weeks and 1 year postprocedure. Subsequent yearly MRIs were recommended but not required. The primary outcomes, pain and function, were assessed by using the Lumbar Spine Outcomes Questionnaire. An “excellent” outcome required complete pain relief according to the Lumbar Spine Outcomes Questionnaire scale, discontinuation of all pain medications and treatments, and improvement or stabilization of other cyst-linked neurologic signs and symptoms so that no further treatments were required. Patients also had to report satisfaction with the

Table 1: Imaging findings

Findings	No. of Patients
Position/No. of root nerves involved	
Unilateral, single root	113
Bilateral, single root	78
Bilateral, ≥ 2 roots	22
Nerve root localization	
L4	1
L5	1
S1	16
S2	142
S3	120
S4–S5	9
Aspirated cyst size, cm	
1–2	1
2–3	111
3–4	32
>4	8

outcome of their procedure and willingness to undergo it again for the same result. A “good/satisfactory” outcome required pain to have “improved quite a bit” on the Lumbar Spine Outcomes Questionnaire scale plus discontinuation of narcotic analgesics. Neurologic deficits had to be commensurate with adequate function or no further progression. Patients also had to be satisfied with the results and not seeking further treatment. All outcomes other than “excellent” or “good/satisfactory” were reported as treatment failures even if some improvement was noted.

RESULTS

The 213 patients described in this article had all been followed for at least 6 months by the time of submission, with 192 (90.1%) of these patients having been followed for 1 year and 177 (83.1%) having been followed for between 3 and 6 years.

Characterization of Cysts

Overall, the 213 patients treated had 289 cysts among them. One hundred forty-four patients had unilateral cysts and symptoms, and 69 patients had bilateral cysts. Multiple cysts ranged from 2 to 9, and the average was 3 for each patient in whom multiple cysts were treated bilaterally. Nine patients had S4 or S5 cysts, but none were symptomatic in isolation. These imaging findings are summarized in Table 1.

Neurologic Symptoms and Signs

Local pain in the region of the cyst that was aggravated by sitting down was the most common symptom in our cohort, though S1, S2 sciatica and neuropathy were also prevalent. Patients with isolated S2 root cysts and no evidence of S1 nerve root compression characteristically had sciatica proceeding no further than the medial heel and immediately adjacent sole. Additionally, many patients had generalized sacral and/or lumbar pain; pelvic and/or perineal pain; and sexual, bladder, or bowel dysfunctions. Common bladder symptoms included incontinence, urinary frequency or urgency, and an inability to fully empty the bladder, while bowel dysfunction tended to involve urgency or mild incontinence. The most common physical neurologic abnormality observed in our patients was an absent ankle reflex. Weakness of plantar flexion was also prevalent, as were cyst-related sensory

Table 2: Neurologic symptoms and signs

Symptom/Sign	No. of Presenting Patients
Local pain	210
L4, L5 neuropathy	2
S1, S2 sciatica	151
S1, S2 neuropathy	137
Generalized sacral/lumbar pain	189
Pelvic/perineal pain	209
Bladder dysfunction	92
Sexual dysfunction	92
Bowel dysfunction	62
Absent Achilles reflex	130
Weakness of plantar flexion	87
Paralysis of plantar flexion	2
Paralysis of dorsiflexion	2
Rectal sphincter tone reduction	61
Bladder sphincter impairment	92
Cyst-related sensory loss	
L4	1
L5	1
S1	16
S2	137
S3, S4, S5	97

loss, reduced rectal sphincter tone, and bladder sphincter impairment. Sensory loss most frequently occurred in the perineal region and usually comanifested with perineal pain. Two patients with cysts that compressed the L5 nerve root exhibited weakness of dorsiflexion and complete footdrop. Table 2 summarizes the presenting signs and symptoms in treated patients.

Aspiration-Injection Outcome

At 1 year postprocedure, “excellent” results had been obtained in 104 patients (54.2%), and “good/satisfactory” results had been obtained in 53 patients (27.6%). Thus, 157 patients (81.8%) in all were initially satisfied with the outcome of treatment. In 7 of the patients who were not satisfactorily treated, the aspiration-injection procedure was not technically feasible. In the remainder, the intervention was performed but failed to yield satisfactory results at 1 year postprocedure.

During the 3- to 6-year follow-up, “excellent” results were obtained in 106 patients (59.9%). This outcome represented an increase from the equivalent statistic at 1 year; all those patients who were classified as having excellent results at 1 year maintained this status into the latter follow-up period, and an additional 2 patients in the “good/satisfactory” category at 1 year now qualified as having excellent results. Twenty-five patients (14.1%) now rated their outcome as “good/satisfactory,” a decline from the number that did so at 1 year. Overall, 131 patients (74.0%) were satisfied with treatment at 3- to 6-year follow-up. Only 2 patients have reported recurrence of symptoms after >6 years.

Table 3 presents a breakdown of the aspiration-injection therapy outcomes with respect to individual signs and symptoms.

Re-Aspiration

Twenty-three patients (10.8% of the treated cohort) underwent re-aspiration within the first 6 months due to recurrent symptoms after immediate short-term relief. Thirteen patients (6.1% of the treated cohort) underwent re-aspiration after 6 months. Two of

Table 3: Outcome of aspiration-injection therapy

Symptom/Sign	Outcome		
	Excellent	Good	Unchanged
Local pain	87 (41.4%)	72 (34.3%)	51 (24.3%)
Sciatica/neuropathy	81 (53.6%)	32 (21.2%)	38 (25.2%)
Perineal pain/sensory loss	86 (41.4%)	70 (33.5%)	53 (25.4%)
Bladder/sexual dysfunction	30 (32.6%)	38 (41.3%)	24 (26.1%)
Bowel dysfunction	22 (35.5%)	23 (37.1%)	17 (27.4%)
Plantar flexion weakness	44 (50.6%)	20 (23.0%)	23 (26.4%)
Plantar flexion paralysis	0 (0%)	0 (0%)	2 (100%)
Dorsiflexion paralysis	0 (0%)	0 (0%)	2 (100%)
Rectal sphincter reduction	22 (36.1%)	23 (37.7%)	16 (26.2%)

these had the procedure between 6 and 12 months after the initial aspiration. In 7, re-aspiration was undertaken after the first year, and in 3, after 2 years. One re-aspiration failed, but all the others conferred satisfactory relief again. One patient underwent 3 re-aspirations for recurrent symptoms at 2-year intervals. Repeat MR imaging demonstrated fluid-filled cysts in all patients who underwent re-aspiration, indicating cyst reaccumulation following the initial procedure.

Complications

There were no documented infections or nerve injuries in the treated cohort. One patient had a mild nonspecific allergic reaction with systemic hives, which led to overnight hospitalization as a precaution, but they resolved without incident. Three patients appeared to experience elevated inflammation; all inflammation resolved without treatment during 2–4 weeks, however.

Seven patients had symptoms of spinal fluid leak and required a postprocedure blood patch for control. Twenty patients had increased sciatica following the procedure, which resolved within <3 months. One patient had increased sciatica that persisted for >3 months but eventually resolved. Seven patients had severely increased local pain; this resolved in 6 of these patients within 3 months. Three patients described an increase in all symptoms, including bowel and bladder dysfunction, immediately following injection, though all were transient and resolved within 3 months. There was no incidence of aseptic meningitis.

Surgical Outcome

Patients who had been referred for surgery initially and 11 patients who failed aspiration and were subsequently referred for surgery were followed on the same schedule used for patients undergoing aspiration. Of the initial 34 patients referred for surgery, 31 (91.2%) achieved excellent or satisfactory relief and were satisfied with their surgical outcome. The remaining 3 patients underwent surgery that proved to be partially successful, but they continued to have symptoms afterward. Nonetheless, no worsening of patients’ conditions or significant increases in neurologic deficits resulted from surgery in these cases. Of the 11 patients who failed aspiration and were referred to surgery, all had successful relief of symptoms.

DISCUSSION

Contrary to popular sentiments in the medical community, current data indicate that at least some TCs are symptomatic. Beyond the simple correlational finding that a consistent set of symptoms

is associated with certain cysts, perhaps the strongest evidence for this position is the well-documented effectiveness of surgical treatment of apparently symptomatic cysts. Since Tarlov described the successful resection of symptomatic perineurial cysts in 1953,¹⁰ there has been a steady progression of case reports and small surgical series that reported successful surgical treatment of such cysts with concomitant relief of patient symptoms and improvement in their neurologic dysfunction.^{19–32} If one accepts the authors' criteria for success, collation of the outcomes of these studies indicates that 88.6% of patients were satisfactorily relieved of symptoms with relatively low morbidity and mortality (no deaths or serious neurologic worsening were reported). Similarly, this study found that 91.2% of the 34 patients referred directly for surgical obliteration (as opposed to aspiration-injection treatment) of their cysts achieved excellent or satisfactory outcomes, while the remainder reported at least some improvement and had no worsening of symptoms or neurologic signs. Relief of symptoms and signs following treatment has long been used in neurosurgery to justify attribution of both to specific pathology; the success of herniated disc excision and decompression of spinal stenosis, for instance, has (supported by excellent clinical research data) helped cement symptomatic attribution to their respective pathologies. As such, this body of evidence strongly supports the contentions that some TCs are symptomatic and that these symptoms can be relieved by surgical intervention.

Such a position is also bolstered by the favorable results obtained by several studies^{13,33–37} that treated symptomatic TCs with variants of the aspiration-injection technique, including the current article. Moreover, we believe that our data help justify the image-guided aspiration of probable symptomatic cysts and their injection with fibrin sealant as a less-invasive alternative treatment to surgical measures. The initial and long-term success rates for this technique are high enough to hold promise for its adoption as an adequate and efficacious therapy option, with 81.8% of treated patients satisfied with the intervention in terms on its effects on their symptoms at 1 year postprocedure and 74.0% satisfied at 3- to 6-year follow-up. Additionally, our data indicate that aspiration-injection treatment is associated with low morbidity and adverse events: No instances of neurologic injury occurred among those treated in our cohort, and only 8 patients had minor complications (all of which resolved without need for further operations). Only 4 patients reported worsened pain following the procedure but 2 of these recovered shortly afterward and a third was lost to follow-up.

Of special note is the utter lack of instances of postprocedural aseptic meningitis (reported by Patel et al³⁴ to have occurred in 75% of patients) in our series; we surmise this may be because we treated only narrow-neck cysts, thus avoiding fibrin reflux into the thecal sac and subarachnoid space. That all of the 11 patients who failed aspiration treatment were subsequently successfully treated with surgery also indicates that the former procedure does not reduce the chance or extent of success for the latter; this indication reinforces the potential of aspiration-injection as a useful first-option treatment for TC.

The simple discovery of a cyst does not justify attribution of the symptoms to that cyst, but cysts of <10 mm have, in our experience, occasionally been symptomatic. Attribution should

be based on the location of the cyst and the ability of these factors to explain (via likely effects on cyst-bearing or neighboring nerve roots) local pain and associated signs and symptoms, as well as temporary relief of symptoms with controlled diagnostic blockade of cyst-bearing nerve roots and the absence of another plausible generator to explain pain and other signs or symptoms. One should not overstate the prevalence of symptomatic Tarlov cysts, especially the prevalence of symptomatic Tarlov cysts that require surgical or percutaneous intervention. In this study, a considerable proportion of patients of the larger group of referred patients were found to be adequately managed by pharmacologic means alone without significant evidence of progression.

Why are these cysts symptomatic in the first place? Certainly, the pathologic changes associated with perineurial cysts are rather striking: Nerves within the cyst-bearing dorsal nerve roots, structures notoriously sensitive to compression, may be distorted, compressed, and injured by the bulging cyst, and adjacent nerves are often also compressed.^{1,10} Given that afferent nerves populate this area, one may make a direct link between such pathologic changes and the (not infrequently) accompanying radicular symptoms, such as neuropathic pain, paresthesias, and sensory loss/neurophysiologic abnormalities. Additionally, cyst pressure is known to be great enough to erode sacral bone and has been hypothesized to sensitize dural and/or periosteal nociceptors.^{10,39} It is possible that this second mechanism is primarily responsible for the local, nociceptive pain that often characterizes symptomatic cysts. Meanwhile, the worsening of both radicular and local symptoms with time could be attributed to the gradual enlargement that some cysts may undergo.^{1,17}

Finally, one should wonder why the fibrin sealant used in the aspiration-injection procedure would be effective in treating symptomatic TCs for the long-term, because the compound is slowly absorbed in the body so that permanent cyst obliteration would not occur. Our underlying hypothesis (shared by Patel et al³⁴) was that the injection of sealant into the cyst would thicken the wall of the cyst via fibrosis and block the 1-way valve at the neck of the cyst, reducing the entry of spinal fluid (and thereby preventing the cyst from distending and compressing local nerves or stimulating nearby nociceptors). This hypothesis remains unproven from these data. Still, some support exists for such a position. In the case of subsequent neurosurgical procedure after the injection of fibrin sealant, the formation of a thin impermeable membrane is reported to be evident in the operative site.

CONCLUSIONS

Despite widespread belief to the contrary, it has been known for some 70 years that perineurial cysts are sometimes symptomatic and that associated symptoms and signs may be relieved by successful treatment of the troublesome cyst. Surgical methods are effective but are often complicated by infection, postoperative CSF leak, or damage to neural tissue; these make them an imperfect first-option treatment and suggest the need for a percutaneous image-guided approach. The aspiration-injection technique described herein constitutes a safe and efficacious treatment option, and one that holds promise for relieving cyst-related symptoms in many patients with very small risk.

REFERENCES

1. Tarlov IM. **Spinal perineurial and meningeal cysts.** *J Neurol Neurosurg Psychiatry* 1970;33:833–43 [CrossRef Medline](#)
2. Goyal RN, Russell NA, Benoit BG, et al. **Intraspinal cysts: a classification and literature review.** *Spine (Phila Pa 1976)* 1987;12:209–13 [CrossRef Medline](#)
3. Rexed B. **Arachnoidal proliferations with cyst formation in human spinal nerve roots at their entry into the intervertebral foramina: preliminary report.** *J Neurosurg* 1947;4:414–21 [CrossRef Medline](#)
4. Tarlov IM. **Perineurial cysts of the spinal nerve roots.** *Arch Neurol Psychiatry* 1938;40:1067–74 [CrossRef](#)
5. Tarlov IM. **Cysts (perineurial) of the sacral roots: another cause (removable) of sciatic pain.** *J Am Med Assoc* 1948;138:740–44 [CrossRef Medline](#)
6. Tarlov IM. **Cysts of the sacral nerve roots: clinical significance and pathogenesis.** *AMA Arch Neurol Psychiatry* 1952;68:94–108 [CrossRef Medline](#)
7. Tarlov IM. **Cysts (perineurial) of the sacral nerve roots: another cause of the sciatic or sacral cauda equina syndrome.** *J Neuropathol Exp Neurol* 1952;11:88–89 [Medline](#)
8. Tarlov IM. **Cysts of sacral nerve roots: pathogenesis and clinical significance.** *AMA Arch Neurol Psychiatry* 1953;69:391–92 [Medline](#)
9. Tarlov IM. **Sacral nerve-root cysts: pathogenesis and clinical significance.** *J Nerv Ment Dis* 1953;117:156–57 [CrossRef Medline](#)
10. Tarlov IM. **Sacral Nerve-Root Cysts: Another Cause of the Sciatic or Cauda Equina Syndrome.** Springfield: Charles C. Thomas; 1953
11. Abbott KH, Leimbach WH, Retter RH. **The role of perineurial sacral cysts in the sciatic and sacrococcygeal syndromes: a review of the literature and report of 9 cases.** *J Neurosurg* 1957;14:5–21 [CrossRef Medline](#)
12. Cattaneo L, Pavesi G, Mancia D. **Sural nerve abnormalities in sacral perineurial (Tarlov) cysts.** *J Neurol* 2001;248:623–24 [CrossRef Medline](#)
13. Paulsen RD, Call GA, Murtagh FR. **Prevalence and percutaneous drainage of cysts of the sacral nerve root sheath (Tarlov cysts).** *AJNR Am J Neuroradiol* 1994;15:293–97; discussion 298–99 [Medline](#)
14. Oaklander AL, Long DM, Larvie M, et al. **Case records of the Massachusetts General Hospital: Case 7–2013—a 77-year-old woman with long-standing unilateral thoracic pain and incontinence.** *N Engl J Med* 2013;368:853–61 [CrossRef Medline](#)
15. Isono M, Hori S, Konishi Y, et al. **Ehlers-Danlos syndrome associated with multiple spinal meningeal cysts: case report.** *Neurol Med Chir (Tokyo)* 1999;39:380–83 [CrossRef](#)
16. Doi H, Sakurai S, Ida M, et al. **A case of sacral meningeal cyst with Marfan syndrome [in Japanese].** *No Shinkei Geka* 1999;27:847–50 [Medline](#)
17. Rodziewicz GS, Kaufman B, Spetzler RF. **Diagnosis of sacral perineurial cysts by nuclear magnetic resonance.** *Surg Neurol* 1984; 22:50–52 [CrossRef Medline](#)
18. Langdown AJ, Grundy JR, Birch NC. **The clinical relevance of Tarlov cysts.** *J Spinal Disord Tech* 2005;18:29–33 [CrossRef Medline](#)
19. Hiers RH, Long D, North RB, et al. **Hiding in plain sight: a case of Tarlov perineurial cysts.** *J Pain* 2010;11:833–37 [CrossRef Medline](#)
20. Bartels RH, van Overbeke JJ. **Lumbar cerebrospinal fluid drainage for symptomatic sacral nerve root cysts: an adjuvant diagnostic procedure and/or alternative treatment? Technical case report.** *Neurosurgery* 1997;40:861–64; discussion 864–65 [CrossRef Medline](#)
21. Morio Y, Nanjo Y, Nagashima H, et al. **Sacral cyst managed with cyst-subarachnoid shunt: a technical case report.** *Spine* 2001;26: 451–53 [CrossRef Medline](#)
22. Siqueira EB, Schaffer L, Kranzler LI, et al. **CT characteristics of sacral perineurial cysts: report of two cases.** *J Neurosurg* 1984;61:596–98 [CrossRef Medline](#)
23. Sá MC, Sá RC. **Tarlov cysts: report of four cases [in Portuguese].** *Arq Neuropsiquiatr* 2004;62:689–94 [CrossRef Medline](#)
24. Tanaka M, Nakahara S, Ito Y, et al. **Surgical results of sacral perineurial (Tarlov) cysts.** *Acta Med Okayama* 2006;60:65–70 [Medline](#)
25. Nishiura I, Koyama T, Handa J. **Intrasacral perineurial cyst.** *Surg Neurol* 1985;23:265–69 [CrossRef Medline](#)
26. Voyadzis JM, Bhargava P, Henderson FC. **Tarlov cysts: a study of 10 cases with review of the literature.** *J Neurosurg* 2001;95:25–32 [Medline](#)
27. Strully KJ, Heiser S. **Lumbar and sacral cysts of meningeal origin.** *Radiology* 1954;62:544–49 [CrossRef Medline](#)
28. Yücesoy KK, Naderi S, Ozer H, et al. **Surgical treatment of sacral perineurial cysts: a case report.** *Kobe J Med Sci* 1999;45:245–50 [Medline](#)
29. Mummaneni PV, Pitts LH, McCormack BM, et al. **Microsurgical treatment of symptomatic sacral Tarlov cysts.** *Neurosurgery* 2000; 47:74–78; discussion 78–79 [CrossRef Medline](#)
30. Guo D, Shu K, Chen R, et al. **Microsurgical treatment of symptomatic sacral perineurial cysts.** *Neurosurgery* 2007;60:1059–65; discussion 1065–66 [CrossRef Medline](#)
31. Rasmussen MM, Clemmensen D, Karabegovic S, et al. **A novel microsurgical method for the treatment of spinal nerve root cysts.** *Dan Med J* 2012;59:A4539 [Medline](#)
32. Caspar W, Papavero L, Nabhan A, et al. **Microsurgical excision of symptomatic sacral perineurial cysts: a study of 15 cases.** *Surg Neurol* 2003;59:101–05; discussion 105–06 [CrossRef Medline](#)
33. Lee JY, Impekoven P, Stenzel W, et al. **CT-guided percutaneous aspiration of Tarlov cyst as a useful diagnostic procedure prior to operative intervention.** *Acta Neurochir (Wien)* 2004;146:667–70 [CrossRef Medline](#)
34. Patel MR, Louie W, Rachlin J. **Percutaneous fibrin glue therapy of meningeal cysts of the sacral spine.** *AJR Am J Roentgenol* 1997;168: 367–70 [CrossRef Medline](#)
35. Zhang T, Li Z, Gong W, et al. **Percutaneous fibrin glue therapy for meningeal cysts of the sacral spine with or without aspiration of the cerebrospinal fluid.** *J Neurosurg Spine* 2007;7:145–50 [CrossRef Medline](#)
36. Murphy K, Wyse G, Schnupp S, et al. **Two-needle technique for the treatment of symptomatic Tarlov cysts.** *J Vasc Interv Radiol* 2008;19: 771–73 [CrossRef Medline](#)
37. Wilkins RH. **Intraspinal cysts.** In: Wilkins RH, Rengachary SS, eds. *Neurosurgery*. New York: McGraw-Hill; 1985:2061–70
38. Bendebba M, Dizerega GS, Long DM. **The Lumbar Spine Outcomes Questionnaire: its development and psychometric properties.** *Spine J* 2007;7:118–32 [CrossRef Medline](#)
39. Dastur HM. **The radiological appearances of spinal extradural arachnoid cysts.** *J Neurol Neurosurg Psychiatry* 1963;26:231–35 [CrossRef Medline](#)